IL-37 Expression is Upregulated in Patients with Tuberculosis and Induces Macrophages Towards an M2-like Phenotype

Scand J Immunol. 2015 Oct;82(4):370-9. doi: 10.1111/sji.12326.

Abstract

Interleukin-37 (IL-37), a member of the IL-1 family, primarily functions as an anti-inflammatory cytokine, reducing inflammation and suppressing the immune response. However, the expression and role of IL-37 in tuberculosis (TB) remains unknown. We aimed to measure serum levels of IL-37 and several important cytokines in 25 patients with active TB and to analyse their association with disease activity. We found that IL-37 levels decreased in patients with TB and recovered after treatment. IL-37 levels negatively correlated with the serum concentration of IFN-γ and IL-12 but positively correlated with IL-10 and TGF-β levels. After IL-37, secretion was blocked in peripheral blood mononuclear cells from active patients with TB, IFN-γ and IL-10 production was significantly upregulated; this was not observed in healthy donors or patients after treatment. IL-37 knockdown significantly enhanced the phagocytic activity of THP1-derived macrophages towards Mycobacterium tuberculosis (M. tb). M1/M2 polarization-associated markers were detected simultaneously, and IL-37 induced a phenotypic shift in THP1-derived macrophages towards a high CD206(+) and low CD86(+) macrophage subtype. Furthermore, this phenotypic shift was accompanied by upregulated mRNA levels of arginase 1, TGF-β and IL-10, which are characteristic hallmarks of M2 macrophages. In conclusion, our results suggest that increased levels of IL-37 in patients with TB are associated with IFN-γ, IL-12, IL-10 and TGF-β levels and that IL-37 plays a pathological role in TB infection by inhibiting the production of pro-inflammatory cytokines and inducing macrophages towards an M2-like phenotype. Thus, IL-37 may be a novel research target to understand the pathogenesis of TB infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Arginase / genetics
  • B7-2 Antigen / metabolism
  • Cell Differentiation / immunology
  • Cells, Cultured
  • Ethambutol / therapeutic use
  • Female
  • Humans
  • Interferon-gamma / blood
  • Interleukin-1 / biosynthesis*
  • Interleukin-1 / blood
  • Interleukin-1 / genetics
  • Interleukin-10 / blood
  • Interleukin-10 / genetics
  • Interleukin-12 Subunit p35 / blood
  • Isoniazid / therapeutic use
  • Lectins, C-Type / metabolism
  • Macrophages / cytology*
  • Macrophages / immunology*
  • Male
  • Mannose Receptor
  • Mannose-Binding Lectins / metabolism
  • Middle Aged
  • Mycobacterium tuberculosis / immunology*
  • Nitric Oxide / metabolism
  • Phagocytosis / immunology
  • Phenotype
  • Pyrazinamide / therapeutic use
  • RNA Interference
  • RNA, Messenger / biosynthesis
  • RNA, Small Interfering
  • Receptors, Cell Surface / metabolism
  • Rifampin / therapeutic use
  • Transcriptional Activation
  • Transforming Growth Factor beta / blood
  • Transforming Growth Factor beta / genetics
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / immunology*
  • Tuberculosis, Pulmonary / metabolism
  • Up-Regulation

Substances

  • Antitubercular Agents
  • B7-2 Antigen
  • CD86 protein, human
  • IL10 protein, human
  • IL12A protein, human
  • IL37 protein, human
  • Interleukin-1
  • Interleukin-12 Subunit p35
  • Lectins, C-Type
  • Mannose Receptor
  • Mannose-Binding Lectins
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Cell Surface
  • Transforming Growth Factor beta
  • Interleukin-10
  • Pyrazinamide
  • Nitric Oxide
  • Interferon-gamma
  • Ethambutol
  • ARG1 protein, human
  • Arginase
  • Isoniazid
  • Rifampin